Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | GRK5 | P34947 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918530 | 0.83 | LRRK2 (0.38) | LRRK2SYKIGF1RPDE4APDE4B | |
| SCHEMBL9921648 | 0.78 | LRRK2 (0.39) | LRRK2MKNK2SYKTTKPDE4A | |
| SCHEMBL9918544 | 0.76 | SMN1; SMN2 (0.44) | LRRK2SYK | |
| SCHEMBL9918524 | 0.73 | TTBK1 (0.41) | LRRK2 | |
| SCHEMBL9918528 | 0.73 | SYK (0.32) | SYKIGF1RKCNH2 | |
| SCHEMBL9918521 | 0.72 | IGF1R (0.34) | LRRK2IGF1RGRK5 | |
| SCHEMBL9918518 | 0.71 | LRRK2 (0.37) | LRRK2 | |
| SCHEMBL9918519 | 0.71 | IGF1R (0.33) | LRRK2SYKIGF1RGRK5KCNH2 | |
| SCHEMBL12832928 | 0.70 | LRRK2 (0.45) | LRRK2 | |
| SCHEMBL9918481 | 0.70 | LRRK2 (0.42) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | LRRK2 1567/4885MKNK2 108/4885SYK 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.